BeiGene Announces Pricing of $750 Million Public Offering
January 17 2018 - 11:21PM
BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical
company focused on developing and commercializing innovative
molecularly targeted and immuno-oncology drugs for the treatment of
cancer, today announced the pricing of its follow-on public
offering of 7,425,750 American Depositary Shares (ADSs), each
representing 13 of its ordinary shares, par value $0.0001 per
share, at a price to the public of $101.00 per ADS. The gross
proceeds to BeiGene from the offering, before deducting
underwriting discounts and commissions and other offering expenses,
are expected to be approximately $750 million. In addition, BeiGene
has granted the underwriters a 30-day option to purchase up to an
additional 495,050 ADSs at the public offering price, less
underwriting discounts and commissions. The offering is expected to
close on January 22, 2018, subject to customary closing conditions.
BeiGene intends to use proceeds from the offering for working
capital and general corporate purposes, including research and
development activities.
Goldman Sachs & Co. LLC, Morgan Stanley, Cowen, and Leerink
Partners are acting as joint book-running managers. William Blair
& Company, L.L.C. is acting as the co-manager.
The securities described above are being offered pursuant to an
automatically effective shelf registration statement that was
previously filed with the U.S. Securities and Exchange Commission
(SEC). A preliminary prospectus supplement relating to and
describing the terms of the offering was filed with the SEC on
January 16, 2018. The final prospectus supplement relating to the
offering will be filed with the SEC and will be available on the
SEC’s website at www.sec.gov. When available, copies of the final
prospectus supplement and the accompanying prospectus relating to
these securities may be obtained for free from the offices of
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, NY 10282, telephone: 1-866-471-2526, or
email: prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, NY 10014; Cowen and Company, LLC, c/o Broadridge Financial
Services, 1155 Long Island Avenue, Edgewood, NY, 11717, United
States, Attn.: Prospectus Department or by calling 1-631-274-2806;
or Leerink Partners LLC, Attention: Syndicate Department, One
Federal Street, 37th Floor, Boston, MA 02110, by telephone at
800-808-7525, ext. 6132 or by email at syndicate@leerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor may there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About BeiGene
BeiGene is a global, commercial-stage, research-based
biotechnology company focused on molecularly targeted and
immuno-oncology cancer therapeutics. With a team of over 850
employees in China, the United States, and Australia, BeiGene is
advancing a pipeline consisting of novel oral small molecules and
monoclonal antibodies for cancer. BeiGene is also working to create
combination solutions aimed to have both a meaningful and lasting
impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle
albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA®
(azacitidine) in China under a license from Celgene
Corporation.1
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to BeiGene’s
expectations regarding the anticipated closing date. Actual results
or developments may differ materially from those projected or
implied in these forward-looking statements. Factors that may cause
such a difference include risks and uncertainties related to
completion of the public offering on the anticipated terms or at
all, market conditions and the satisfaction of customary closing
conditions related to the public offering. More information about
the risks and uncertainties faced by BeiGene is contained or
incorporated by reference in the preliminary prospectus supplement
related to the public offering filed with the SEC. BeiGene
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Investor Contact
Lucy Li, Ph.D.+1 781-801-1800ir@beigene.com
Media Contact
Liza Heapes+ 1 857-302-5663media@beigene.com
1 ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of
Celgene Corporation.
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Sep 2023 to Sep 2024